Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Clinical trial Stories

2014-04-19 23:00:42

ReportsnReports.com adds the latest report on “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014” to its store. Order a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=279869. Dallas, TX (PRWEB) April 19, 2014 This report provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial...

2014-04-18 23:04:04

Panel at DIA Annual Meeting to Explore Leveraging Data and Analytics to Enhance Collaboration Washington (PRWEB) April 18, 2014 The impact of “big data” on the partnerships between contract research organizations (CROs) and clinical trial sponsors will be discussed at the DIA 2014 50th Annual Meeting, June 15 to 19, in San Diego. The “Big Data, Big Impact: New Levels of Strategic Partnerships Between Sponsors-CROs” forum, held on June 17 at 8 a.m. in the San Diego Convention...

2014-04-17 12:29:28

LONDON, April 17, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Brain Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/brain_cancer_global_clinical_trials_review_h1_2014.htmlBrain Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Brain Cancer Global Clinical Trials Review, H1, 2014" provides data on the Brain Cancer clinical trial scenario. This report...

2014-04-17 00:21:10

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The proceeds from this financing have supported Heart Metabolics Limited in acquiring a Phase 3-ready drug candidate and related preclinical drug...

2014-04-16 23:09:48

New webinar will focus on how to handle and prevent missing data to improve clinical trial data credibility. The live discussion takes place on Friday, May 2, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 16, 2014 Missing data is common in most clinical trials because some subjects withdraw from the trial before the crucial final measurements. Without those final measurements, our picture of the new treatment is imperfect, and it could actually be wrong. What...

2014-04-16 12:29:54

PLYMOUTH MEETING, Pa., April 16, 2014 /PRNewswire/ -- ePharmaSolutions, a leading provider of eClinical solutions announced the results of the initial pilot studies for its patient matching and triaging solution, ReferralPlus(TM), that suggest a significant improvement in match rates for people who are actively searching for clinical trials in which to participate. "We are absolutely thrilled with the results of these pilots and want to thank all of the pharmaceutical companies who helped...

2014-04-16 08:34:21

Clinical Results Open Significant Market Opportunity for BioElectronics Corp. FREDERICK, Md., April 16, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced reports on preliminary results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. An abstract on the interim analysis of the osteoarthritis (OA) knee pain study has been accepted by...

2014-04-15 23:12:11

Achieve is conducting a randomized, active and placebo-controlled study to evaluate the efficacy and safety of an experimental drug for preventing flares and reducing serum uric acid in patients with gout. Birmingham, AL (PRWEB) April 15, 2014 *To see if you qualify for this Gout Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and...

2014-04-15 12:30:48

Major Production Increase Being Undertaken To Meet Growing Demand BETHESDA, Md., April 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million...

2014-04-15 08:30:06

Purchase adds global regulatory writing and submission services to Certara's drug development consulting expertise NEW YORK, April 15, 2014 /PRNewswire/ -- Arsenal Capital Partners, a leading New York based private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies, announced today the acquisition of Synchrogenix, the leading regulatory writing and related services firm. Synchrogenix provides services to pharmaceutical,...